84 related articles for article (PubMed ID: 18705947)
1. The albumin in acute stroke trial (ALIAS); design and methodology.
Hill MD; Moy CS; Palesch YY; Martin R; Dillon CR; Waldman BD; Patterson L; Mendez IM; Ryckborst KJ; Tamariz D; Ginsberg MD;
Int J Stroke; 2007 Aug; 2(3):214-9. PubMed ID: 18705947
[TBL] [Abstract][Full Text] [Related]
2. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report.
Ginsberg MD; Palesch YY; Hill MD
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1323-6. PubMed ID: 17073812
[TBL] [Abstract][Full Text] [Related]
3. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results.
Ginsberg MD; Hill MD; Palesch YY; Ryckborst KJ; Tamariz D
Stroke; 2006 Aug; 37(8):2100-6. PubMed ID: 16809571
[TBL] [Abstract][Full Text] [Related]
4. The Membrane-Activated Chelator Stroke Intervention (MACSI) Trial of DP-b99 in acute ischemic stroke: a randomized, double-blind, placebo-controlled, multinational pivotal phase III study.
Rosenberg G; Bornstein N; Diener HC; Gorelick PB; Shuaib A; Lees K;
Int J Stroke; 2011 Aug; 6(4):362-7. PubMed ID: 21645269
[TBL] [Abstract][Full Text] [Related]
5. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis.
Palesch YY; Hill MD; Ryckborst KJ; Tamariz D; Ginsberg MD
Stroke; 2006 Aug; 37(8):2107-14. PubMed ID: 16809570
[TBL] [Abstract][Full Text] [Related]
6. [Prospects of thrombolytic therapy for acute ischemic stroke].
Nakashima T; Minematsu K
Brain Nerve; 2009 Sep; 61(9):1003-12. PubMed ID: 19803399
[TBL] [Abstract][Full Text] [Related]
7. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
Hsu YC; Sung SF; Ong CT; Wu CS; Su YH
Acta Neurol Taiwan; 2009 Mar; 18(1):14-20. PubMed ID: 19537569
[TBL] [Abstract][Full Text] [Related]
8. Safety, effectiveness, and practicality of endovascular therapy within the first 3 hours of acute ischemic stroke onset.
Mathews MS; Sharma J; Snyder KV; Natarajan SK; Siddiqui AH; Hopkins LN; Levy EI
Neurosurgery; 2009 Nov; 65(5):860-5; discussion 865. PubMed ID: 19834397
[TBL] [Abstract][Full Text] [Related]
9. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
[TBL] [Abstract][Full Text] [Related]
10. Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial.
Amlie-Lefond C; Chan AK; Kirton A; deVeber G; Hovinga CA; Ichord R; Stephens D; Zaidat OO;
Neuroepidemiology; 2009; 32(4):279-86. PubMed ID: 19223687
[TBL] [Abstract][Full Text] [Related]
11. Correction: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480].
den Hertog HM; van der Worp HB; van Gemert HM; Algra A; Kappelle LJ; van Gijn J; Koudstaal PJ; Dippel DW;
BMC Cardiovasc Disord; 2008 Nov; 8():29. PubMed ID: 18983661
[TBL] [Abstract][Full Text] [Related]
12. Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
Mendioroz M; Fernández-Cadenas I; Alvarez-Sabín J; Rosell A; Quiroga D; Cuadrado E; Delgado P; Rubiera M; Ribó M; Molina C; Montaner J
Cerebrovasc Dis; 2009; 28(2):143-50. PubMed ID: 19546541
[TBL] [Abstract][Full Text] [Related]
13. Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network.
Dowlatshahi D; Hakim A; Fang J; Sharma M;
Int J Stroke; 2009 Oct; 4(5):328-34. PubMed ID: 19765119
[TBL] [Abstract][Full Text] [Related]
14. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
Pundik S; McWilliams-Dunnigan L; Blackham KL; Kirchner HL; Sundararajan S; Sunshine JL; Tarr RW; Selman WR; Landis DM; Suarez JI
J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.
Bolland K; Whitehead J; Cobo E; Secades JJ
Pharm Stat; 2009; 8(2):136-49. PubMed ID: 18637642
[TBL] [Abstract][Full Text] [Related]
16. Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients.
Nam HS; Lee KY; Han SW; Kim SH; Lee JY; Ahn SH; Kim DJ; Kim DI; Nam CM; Heo JH
J Neurol Sci; 2009 Jun; 281(1-2):69-73. PubMed ID: 19304298
[TBL] [Abstract][Full Text] [Related]
17. A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.
LaMonte MP; Bahouth MN; Magder LS; Alcorta RL; Bass RR; Browne BJ; Floccare DJ; Gaasch WR;
Ann Emerg Med; 2009 Sep; 54(3):319-27. PubMed ID: 19101059
[TBL] [Abstract][Full Text] [Related]
18. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.
Ginsberg MD; Palesch YY; Hill MD; Martin RH; Moy CS; Barsan WG; Waldman BD; Tamariz D; Ryckborst KJ;
Lancet Neurol; 2013 Nov; 12(11):1049-58. PubMed ID: 24076337
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of MRI-based selection for recombinant tissue plasminogen activator treatment: responder analysis of outcome in the 3-hour time window.
Sølling C; Hjort N; Ashkanian M; Østergaard L; Andersen G
Cerebrovasc Dis; 2009; 27(3):223-9. PubMed ID: 19176954
[TBL] [Abstract][Full Text] [Related]
20. How important is surrogate consent for stroke research?
Flaherty ML; Karlawish J; Khoury JC; Kleindorfer D; Woo D; Broderick JP
Neurology; 2008 Nov; 71(20):1566-71. PubMed ID: 18753472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
